Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$3.99B	0.43	3.66 million shs	3.84 million shs
ADVM Adverum Biotechnologies	$2.77 -2.5%	$2.42	$1.78 ▼ $9.95	$57.87M	0.7	248,802 shs	120,119 shs
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
ELEV Elevation Oncology	$0.38 -0.1%	$0.35	$0.22 ▼ $3.09	$22.21M	1.48	1.48 million shs	1.16 million shs
MIRO Miromatrix Medical	$3.39	$3.38	$0.91 ▼ $4.35	$92.95M	0.01	80,095 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
ADVM Adverum Biotechnologies	+2.90%	+4.41%	+22.41%	-3.07%	-67.65%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-91.43%
ELEV Elevation Oncology	-1.19%	-0.90%	-1.68%	-2.80%	-87.02%
MIRO Miromatrix Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8794 of 5 stars	3.7	1.0	0.0	0.0	2.9	2.5	3.1
ADVM Adverum Biotechnologies	4.4165 of 5 stars	3.4	4.0	0.0	4.8	1.6	2.5	0.6
APTO Aptose Biosciences	1.032 of 5 stars	3.8	0.0	0.0	0.0	0.0	0.0	0.0
ELEV Elevation Oncology	2.7645 of 5 stars	3.0	5.0	0.0	0.0	2.0	1.7	0.6
MIRO Miromatrix Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	759.21% Upside
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
ELEV Elevation Oncology	2.00	Hold	$3.39	802.86% Upside
MIRO Miromatrix Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELEV, MIRO, ADVM, APTO, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$459.38M	8.69	$0.51 per share	32.68	$1.48 per share	11.30
ADVM Adverum Biotechnologies	$1M	57.87	N/A	N/A	$3.40 per share	0.81
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
MIRO Miromatrix Medical	$958.03K	97.02	N/A	N/A	$1.25 per share	2.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	8/5/2025 (Estimated)
MIRO Miromatrix Medical	-$29.96M	-$1.14	N/A	∞	N/A	-2,861.17%	-120.49%	-90.70%	N/A

Latest ELEV, MIRO, ADVM, APTO, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ELEV Elevation Oncology	-$0.26	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
MIRO Miromatrix Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
ADVM Adverum Biotechnologies	N/A	3.57	3.57
APTO Aptose Biosciences	N/A	1.05	1.05
ELEV Elevation Oncology	0.67	19.40	19.40
MIRO Miromatrix Medical	0.02	3.46	3.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ADVM Adverum Biotechnologies	48.17%
APTO Aptose Biosciences	26.62%
ELEV Elevation Oncology	83.70%
MIRO Miromatrix Medical	29.38%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
ADVM Adverum Biotechnologies	6.00%
APTO Aptose Biosciences	1.33%
ELEV Elevation Oncology	8.10%
MIRO Miromatrix Medical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
MIRO Miromatrix Medical	76	27.42 million	25.99 million	Optionable

ELEV, MIRO, ADVM, APTO, and ADMA Headlines

Recent News About These Companies

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver - Morningstar

June 25, 2025 | morningstar.comM

Intermountain Health patient first to be treated with external bioengineered liver

June 25, 2025 | ksl.comK

Turning pig organs to human organs

October 22, 2024 | mndaily.comM

University of Minnesota Venture Center Director Russ Straate retires

October 16, 2024 | bizjournals.com

BioLargo, Inc.: Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer

September 9, 2024 | finanznachrichten.de

Clyra Medical Technologies Appoints Dr. Steven J. Kavros as Chief Medical Officer

September 9, 2024 | finance.yahoo.com

United Therapeutics to build $100M pig-to-human organ research center in southeast Minnesota

August 15, 2024 | startribune.comS

Walter Reed Army Medical Center

March 2, 2024 | military.comM

Q4 2023 United Therapeutics Corp Earnings Call

February 22, 2024 | uk.finance.yahoo.com

Southwest Virginia scientists are gene-editing pigs for human transplants

December 19, 2023 | cardinalnews.orgC

Best Stocks to Buy Right Now

November 22, 2023 | benzinga.com

Miromatrix Holder Says It Omitted United Therapeutics Deal Info

November 16, 2023 | news.bloomberglaw.comN

Miromatrix Medical GAAP EPS of -$0.24, revenue of $11.17M

November 15, 2023 | msn.com

Miromatrix Reports Third Quarter 2023 Results

November 14, 2023 | finance.yahoo.com

Miromatrix Medical climbs 225% following $140m United Therapeutics bid

October 31, 2023 | proactiveinvestors.com

United Therapeutics agrees to buy Miromatrix Medical

October 31, 2023 | msn.com

United Therapeutics looks to hog bioengineered organ R&D with $91M Miromatrix buy

October 31, 2023 | fiercebiotech.comF

Miromatrix Medical Shares Triple After United Therapeutics Offer

October 31, 2023 | marketwatch.com

United Therapeutics buying Miromatrix for up to $140M

October 30, 2023 | bioworld.comB

Eden Prairie biotech company Miromatrix Medical sells for $91M

October 30, 2023 | startribune.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Why Centene Stock Dropped 40% — And Whether It's a Buy Now
By Leo Miller | July 8, 2025
View Why Centene Stock Dropped 40% — And Whether It's a Buy Now
3 Overbought Stocks Ripe for a Pullback
By Ryan Hasson | July 7, 2025
View 3 Overbought Stocks Ripe for a Pullback

ELEV, MIRO, ADVM, APTO, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Adverum Biotechnologies NASDAQ:ADVM

$2.77 -0.07 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 04:41 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Elevation Oncology NASDAQ:ELEV

$0.38 0.00 (-0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 0.00 (0.00%)

As of 07:36 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Miromatrix Medical NASDAQ:MIRO

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time